Riociguat for the treatment of pulmonary arterial hypertension.
By H. Ghofrani, N. Galiè, F. Grimminger, E. Grünig, M. Humbert, Z. Jing, A. Keogh, D. Langleben, M. O. Kilama, A. Fritsch and 2 more. New England Journal of Medicine, 2013
1,217 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/821c9c3c07b895b3569f220aa52e3d225b716ea4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015, neutral): “Unknown 19/253 (8) 21/247 (9) 13/126 (10) 8/121 (7)”
- Pulmonary arterial hypertension (2013, background): “The Phase III, double-blind, randomized, placebocontrolled PATENT-1 study investigated the efficacy and safety of riociguat in patients with symptomatic PAH [256].”